Skip to main content
. 2023 Jun 15;13(6):991. doi: 10.3390/biom13060991

Figure 5.

Figure 5

Kaplan–Meier analysis of PFS and OS according to the percentage of Treg and exhausted CD8+ T cells in patients treated with crizotinib. (A,B) The difference in PFS between patients with high and low levels of tumour-infiltrating Tregs (A) and exhausted CD8+ T cells (B). (C,D) The difference in OS between patients with high and low levels of tumour-infiltrating Tregs (C) and exhausted CD8+ T cells (D).